With the health and security of millions of Americans on the line, U.S. innovators in the bio-pharmaceutical sector are committing everything they have to the fight against COVID-19. Today, an industry that annually re-invests a greater percentage of its revenues than any other into research and development has committed its R&D resources on an unprecedented scale to a single objective: finding safe and effective means to treat and prevent COVID-19 through therapies and vaccines. 

This is a nationwide effort that currently involves nearly 600 clinical trials in communities across all 50 U.S. states and the District of Columbia. As many as 13 million Americans—one in every 25—are taking part in these trials, sponsored by government and industry and carried out by scientists, doctors, nurses, and caretakers at local universities, hospitals, and clinics in your community and nationwide. The approaches they are testing are available due to investments spanning decades. 

One such is Gilead’s Remdesivir, a drug sprung from nearly 30 years of anti-viral research by the San Francisco-based company.  For more than a decade, Gilead has tested Remdesivir against viral diseases including Ebola, SARS, MERS—and now with heralded results against COVID-19—each time gaining a better understanding of how to counter viral diseases and manage the body’s own immune responses. 

Remdesivir is one in a pipeline of drug candidates that Gilead invests in to produce tomorrow’s cures. Earlier work by Gilead resulted in tremendous breakthroughs on HIV and Hepatitis C, saving millions of lives. The sobering reality, though, industry-wide, is that 90% of drug candidates in the pipeline will fail. Accordingly, companies on the innovative end of the bio-pharmaceutical manufacturing industry depend on revenues from those rare breakthrough successes to fund the ongoing research and development pipelines that enable them to respond quickly and robustly to a pandemic crisis such as COVID-19. 

Too often, these innovators are inappropriately lumped into a broader debate about the systemic costs of healthcare that fails to acknowledge the unique role innovators play in advancing the state of the art — and treating the previously untreatable. The debate also fails to recognize the inherent risk these innovators operate under as medical trailblazers with a business model whose sustainability depends on one successful product financially supporting many other equally important efforts – one of which may be the key to solving the next health crisis. 

Many, including some in the United States, are making proposals that could harm the ability of these businesses to invest in research, development and deployment. They offer glib statements that ignore the value of the research and development investment that enabled breakthrough medicine to be discovered and the next leading discovery to be positioned for success. As the old saying goes, if it is too good to be true, it is. 

In the midst of the COVID-19 pandemic, Americans have taken a greater interest than ever in understanding the process of innovation that leads to a successful vaccine or therapy. That’s great news. But even now, some political leaders are making proposals to impose artificial price controls on the breakthrough medicines that result. That’s a huge problem for innovators who need to keep their eyes on the ball to deliver solutions to COVID-19. 

The U.S. Chamber of Commerce has developed a number of resources for those who are interested in the economics of innovation in the bio-pharmaceutical sector and beyond:

• Discover & Deliver - This interactive map illustrates the vast nationwide effort led by private sector innovators to identify safe and effective Covid-19 vaccines and therapies and manufacture at scale to break the pandemic. 
• Value Ingenuity Innovation Platform - The Value Ingenuity platform showcases the lifecycle and ecosystem for innovation across diverse industry sectors. 
• U.S. Chamber Recommendations to White House Coronavirus Task Force - In April 2020, a U.S. Chamber letter to Vice President Pence as head of the White House Coronavirus Task Force made recommendations for the deployment of public-private partnerships to fight Covid-19. 
• The International Pricing Index: What will be the Impact on Patients, Outcomes, and Innovation? - Chamber-sponsored research looks at the impact of price-fixing proposals on innovative R&D budgets at a firm-specific level. 
• International Business Associations Open Letter to Global Governments - On July 16, the U.S. Chamber of Commerce and other leading global business organizations called on governments worldwide to respect the intellectual property rights that are making Covid-19 solutions possible. 
• Innovation & Creativity Access Barometer – Measuring access to innovative and creative technologies, products, and services in the G-20 countries, this study shows the U.S. with a commanding global lead in policies that result in greater access to health care innovation, new technologies, and creative works.